Dyno Therapeutics is using AI to develop next generation AAV vectors for gene therapies
Co-Founder & CSO Adrian Veres and Head of Stewardship Tyson Bertmaring describe the shortcomings of wild type AAV that Dyno is trying to overcome through AI and how the company thinks about partnership and community.
Brought to you by:
תגובות